0
0
Delhi, December 19, 2024 — AIIMS Delhi has unveiled a groundbreaking antibody-based therapy for recurrent Multiple Myeloma (MM), aiming to make advanced cancer treatments more accessible and affordable for Indian patients. This development, spearheaded by the Department of Medical Oncology at the Dr. B.R. Ambedkar Institute Rotary Cancer Hospital (BRAIRCH), marks a significant milestone in India’s fight against cancer.
MM, a type of blood cancer that is highly prone to recurrence, has historically been treated with CAR-T cell therapy, a cutting-edge but prohibitively expensive option costing over ₹1 crore. The new therapy, developed under the leadership of Dr. Mayank Singh, targets B-cell maturation antigen (BCMA), a critical marker in MM progression.
The innovation promises to revolutionize cancer care in India by reducing the cost of treatment to ₹20 lakh—a dramatic reduction that could make life-saving therapies accessible to a broader patient base. “This indigenous approach not only offers hope to thousands of cancer patients but also positions India as a leader in affordable cancer therapies,” Dr. Singh stated.
The therapy has already secured a patent and is poised to enter clinical trials. These trials aim to validate the treatment’s safety and efficacy, bringing it closer to widespread availability. AIIMS is optimistic that the initiative will bridge the gap in affordable cancer care, providing Indian patients access to cutting-edge therapies previously available only to those with significant financial resources.
This initiative underscores AIIMS Delhi’s commitment to addressing the rising burden of cancer in India through innovative and cost-effective solutions. With this development, India could soon emerge as a hub for affordable, advanced cancer treatments.
Source: The New Indian Express
